PMID- 17237622
OWN - NLM
STAT- MEDLINE
DCOM- 20070320
LR  - 20151119
IS  - 0030-2414 (Print)
IS  - 0030-2414 (Linking)
VI  - 70
IP  - 6
DP  - 2006
TI  - Extracorporeal photodynamic image detection of mouse osteosarcoma in soft tissues 
      utilizing fluorovisualization effect of acridine orange.
PG  - 465-73
AB  - Various imaging methods have been employed for the extracorporeal detection of 
      malignant tumors in the human body, such as scintigraphy and PET; however, none 
      is sufficiently accurate and all are also very expensive. To resolve these 
      issues, we attempted to develop a new imaging technique of photodynamic diagnosis 
      (PDD) with acridine orange (AO). AO has the ability to rapidly and specifically 
      accumulate in malignant tumors and emit brilliant green fluorescence after blue 
      light excitation. In this study, we investigated the feasibility of PDD utilizing 
      the fluorovisualization effect of AO, for the extracorporeal detection of mouse 
      osteosarcoma inoculated into the soft tissues. At 2 h after intravenous 
      administration of 0.1, 0.2, 0.5, 1.0, 2.0 and 5.0 mg/kg AO, the tumor and the 
      surrounding normal tissues were illuminated by blue light. The visual 
      fluorescence contrast and ratio (X) of the difference in fluorescence intensity 
      between the tumor and the surrounding normal tissues were evaluated using a 
      high-resolution digital camera equipped with an absorption filter. In addition, 
      the fluorescence contrast was also detected sequentially at 0.5, 1, 2, 3, 6 and 
      12 h after intravenous administration of AO at 1.0 mg/kg. The results revealed 
      that the optimal condition for clear detection of the tumor was evaluation 2 h 
      after intravenous injection of AO at 0.1 mg/kg, because it provided the best 
      visual contrast on the digital images, and the fluorescence intensity as well as 
      the value of X were higher as compared to the values under other conditions of 
      dose and timing. Based on the results of an acute toxicity study of AO, the 
      estimated LD50 of this substance following intravenous administration was 27.30 
      mg/kg. In conclusion, we believe that PDD using AO administered intravenously may 
      be feasible for the detection of human musculoskeletal sarcomas in the soft 
      tissues at extremities, and this technique might be a less invasive, less 
      expensive, quicker and more accurate imaging modality than other previously 
      reported imaging methods for this purpose.
CI  - Copyright 2006 S. Karger AG, Basel.
FAU - Satonaka, Haruhiko
AU  - Satonaka H
AD  - Department of Orthopedic Surgery, Mie University Faculty of Medicine, Tsu, Japan.
FAU - Kusuzaki, Katsuyuki
AU  - Kusuzaki K
FAU - Matsubara, Takao
AU  - Matsubara T
FAU - Shintani, Ken
AU  - Shintani K
FAU - Wakabayashi, Toru
AU  - Wakabayashi T
FAU - Matsumine, Akihiko
AU  - Matsumine A
FAU - Uchida, Atsumasa
AU  - Uchida A
LA  - eng
PT  - Journal Article
DEP - 20070119
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Fluorescent Dyes)
RN  - F30N4O6XVV (Acridine Orange)
SB  - IM
MH  - *Acridine Orange/toxicity
MH  - Animals
MH  - Cell Line, Tumor
MH  - Feasibility Studies
MH  - Fluorescence
MH  - *Fluorescent Dyes/toxicity
MH  - Mice
MH  - Osteosarcoma/*diagnosis/pathology
MH  - Soft Tissue Neoplasms/*diagnosis/pathology
MH  - Time Factors
EDAT- 2007/01/24 09:00
MHDA- 2007/03/21 09:00
CRDT- 2007/01/24 09:00
PHST- 2006/03/13 00:00 [received]
PHST- 2006/09/14 00:00 [accepted]
PHST- 2007/01/24 09:00 [pubmed]
PHST- 2007/03/21 09:00 [medline]
PHST- 2007/01/24 09:00 [entrez]
AID - 000098874 [pii]
AID - 10.1159/000098874 [doi]
PST - ppublish
SO  - Oncology. 2006;70(6):465-73. doi: 10.1159/000098874. Epub 2007 Jan 19.